24/7 Market News Snapshot 13 October, 2025 – Compugen Ltd (NASDAQ:CGEN)

October 13, 2025

DENVER, Colo., 13 October, 2025 (www.247marketnews.com) – (NASDAQ:CGEN) are discussed in this article.
Compugen Ltd. is experiencing a notable surge in market activity, with shares opening at $1.98 and increasing to $2.26, reflecting a substantial rise of 22.16% from yesterday’s close of $1.85. This upward trend follows a robust trading volume of approximately 1.07 million shares, indicating a growing investor interest that underscores the company’s promising potential in the biotechnology sector.

In tandem with this stock performance, Compugen is set to present significant advancements in its clinical research at the upcoming European Society of Medical Oncology (ESMO) conference. The company has announced the publication of a pooled analysis from Phase 1 clinical trials of its investigational therapy, COM701, which targets platinum-resistant ovarian cancer patients. The analysis, conducted on a cohort of 60 patients, demonstrates notable anti-tumor activity and an encouraging safety profile, paving the way for further exploration of COM701’s potential.

Dr. Oladapo Yeku from Harvard Medical School will present these findings, emphasizing the therapy’s ability to yield durable responses, particularly among patients with lower disease burdens. Dr. Yeku remarked, “The results present a compelling case for the use of COM701 as a viable maintenance therapy, especially for patients who have been heavily pre-treated and are in need of effective ongoing treatment options.”

Eran Ophir, President and CEO of Compugen, highlighted the company’s commitment to addressing the unmet needs of women with platinum-sensitive ovarian cancer. He stated, “Leveraging the unique mechanisms of COM701 provides us with an exciting opportunity to potentially modify the course of their disease.”

Compugen is actively advancing the MAIA-ovarian trial, focusing on COM701 as a maintenance therapy for relapsed platinum-sensitive ovarian cancer, with plans for an interim analysis by the end of 2026. This ongoing research reinforces Compugen’s dedication to expanding its innovative treatment pipeline in the fight against cancer.

Related news for (CGEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.